Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 16, 2024; 12(2): 267-275
Published online Jan 16, 2024. doi: 10.12998/wjcc.v12.i2.267
Survival benefit of concurrent chemoradiotherapy for advanced ampulla of Vater cancer
Chae Hwa Kwon, Hyung Il Seo, Dong Uk Kim, Sung Yong Han, Suk Kim, Nam Kyung Lee, Seung Baek Hong, Ji Hyun Ahn, Young Mok Park, Byeong Gwan Noh
Chae Hwa Kwon, BioMedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea
Hyung Il Seo, Young Mok Park, Byeong Gwan Noh, Department of Surgery, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea
Dong Uk Kim, Sung Yong Han, Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea
Suk Kim, Nam Kyung Lee, Seung Baek Hong, Department of Radiology, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea
Ji Hyun Ahn, Department of Pathology and Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea
Author contributions: Seo HI contributed design of the study; Kwon CH contributed analysis of data; Seo HI and Kwon CH contributed interpretation of data and drafting the article; Kim DU and Han SY contributed review the manuscript; Kim S, Lee NK, Hong SB, Ahn JH, Par YM and Noh BG contributed acquisition of data; all authors have read and approved the final manuscript.
Supported by a Biomedical Research Institute Grant (202300060001) from Pusan National University Hospital.
Institutional review board statement: This study was approved by the Institutional Review Board of Clinical Trial Center in Pusan National University hospital (IRB No. 2303-007-124).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors have no financial relationships to disclose.
Data sharing statement: The data that support the findings of this study are available from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hyung Il Seo, MD, PhD, Surgeon, Department of Surgery, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, 179, Gudeok-ro, Seo-gu, Busan 49241, South Korea. seohi71@pusan.ac.kr
Received: October 31, 2023
Peer-review started: October 31, 2023
First decision: November 28, 2023
Revised: December 7, 2023
Accepted: December 27, 2023
Article in press: December 27, 2023
Published online: January 16, 2024
Core Tip

Core Tip: We examined the potential survival benefits of adjuvant concurrent chemoradiotherapy (CCRT). Our findings indicated that adjuvant CCRT may not provide any survival advantage to patients with ampulla of Vater (AoV) cancer who had T3/T4 or lymph node-positive tumors. Therefore, the use of adjuvant CCRT as a standard approach in the treatment of advanced AoV cancer patients should be reconsidered.